2015 Press Releases


Keyword Search
2017 | 2016 | 2015 | 2014
DateTitle 
12/03/15First Patient Enrolled in Toca 5, Tocagen’s Phase 2/3 Clinical Trial
Study Designed to Serve as a Potential Registrational TrialSAN DIEGO – Dec. 3, 2015 — Tocagen Inc. a clinical-stage, cancer-selective immunotherapy company, today announced that the first patient has been enrolled in the Phase 2 portion of its randomized, controlled Phase 2/3 clinical trial of Toca 511 & Toca FC against current standard of care in patients with first or second recurrence of glioblastoma or anaplastic astrocytoma who are undergoing resection.“The current lack of effective the... 
Printer Friendly Version
11/23/15Tocagen Presents Updated Data at the SNO and SNO-SCIDOT Conferences
  Tocagen Presents Interim Data from Studies Evaluating Toca 511 & Toca FC at the Annual Meeting of the Society for Neuro-Oncology (SNO) SAN DIEGO, – Nov. 23, 2015 – Tocagen Inc., a clinical-stage, cancer-selective immunotherapy company, today announced interim data from ongoing Phase 1 and preclinical studies of Toca 511 in combination with Toca FC were presented at the 20th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO) and the SNO-SCIDOT Joint Co... 
Printer Friendly Version
11/18/15Tocagen Announces Presentations at the SNO and SNO-SCIDOT Conferences
Tocagen to Present Interim Results from Studies Evaluating Toca 511 & Toca FC at the Annual Meeting of the Society for Neuro-Oncology (SNO) SAN DIEGO, – November 18, 2015 – Tocagen Inc., a clinical-stage, cancer-selective immunotherapy company, today announced that interim results from ongoing Phase 1 and preclinical studies of Toca 511 in combination with Toca FC will be presented at the 20th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), to be held Nov... 
Printer Friendly Version
09/10/15Lori Kunkel, M.D., Joins Tocagen’s Board of Directors
Former Chief Medical Officer at Pharmacyclics, Proteolix and Loxo Oncology Brings Expertise in Immuno-Oncology Drug Development and Commercialization SAN DIEGO, – Sept. 10, 2015 – Tocagen Inc., a clinical-stage immuno-oncology company, today announced that Lori Kunkel, M.D., has joined the company’s board of directors. Dr. Kunkel has more than twenty years of experience in oncology and immunology drug development and commercialization, including serving as chief medical officer at Pharmacyc... 
Printer Friendly Version
09/03/15Tocagen to Present at BioCentury’s NewsMakers in the Biotech Industry Conference
SAN DIEGO – Sept. 3, 2015 — Tocagen Inc., a clinical-stage immuno-oncology company, today announced the company will present at the BioCentury 22nd Annual NewsMakers in the Biotech Industry Conference. The presentation will take place on Thursday, Sept. 10, 2015 at 10:30 a.m. ET in room 508 of the Millennium Broadway Hotel in New York City. The presentation will provide a company overview and program update, with a focus on lead immuno-oncology product, Toca 511 & Toca FC, and the Toca 5 piv... 
Printer Friendly Version
08/25/15FDA Grants Orphan Designation for Toca 511 & Toca FC
FDA Grants Orphan Drug Designation for Tocagen’s Toca 511 & Toca FC, an Investigational Immuno-Oncology Treatment for Glioblastoma SAN DIEGO – Aug. 25, 2015 — Tocagen Inc., a clinical-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to the company’s lead immuno-oncology product candidate, Toca 511 & Toca FC, for the treatment of glioblastoma. As previously announced, the investigational drug was granted FDA Fast... 
Printer Friendly Version
07/09/15FDA Grants Fast Track Designation to Tocagen’s Toca 511 & Toca FC for Treatment of Recurrent High Grade Glioma
SAN DIEGO – July 09, 2015 — Tocagen Inc. a clinical-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead immuno-oncology product, Toca 511 & Toca FC, for the treatment of recurrent high grade glioma, which includes glioblastoma and anaplastic astrocytoma. This treatment will enter a registrational study called Toca 5 later this year in patients with recurrent glioblastoma or anaplastic astrocytoma. “Th... 
Printer Friendly Version
06/17/15Tocagen Appoints Asha Das, M.D., as Vice President Clinical Development and Medical Affairs
Experienced Oncology Drug Developer and Neuro-Oncologist will Lead Tocagen’s Registrational Toca 5 Study  Previously Led Activities Surrounding Approval and Launch of Avastin® for Glioblastoma SAN DIEGO, – June 17, 2015 – Tocagen Inc., today announced Asha Das, M.D., has been named vice president of clinical development and medical affairs. Prior to joining Tocagen she held positions of increasing responsibility at Genentech, including leading activities related to the approval and launch ... 
Printer Friendly Version
05/05/15Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors
Executive Previously Led Oncology Clinical Development at Amgen and Novartis, Drug Development Activities at the National Cancer Institute SAN DIEGO – May 5, 2015 — Tocagen Inc. a clinical-stage immuno-oncology company, today announced that David R. Parkinson, M.D., a venture partner at New Enterprise Associates (NEA), has been appointed to the board of directors of Tocagen. Dr. Parkinson has more than twenty years of experience in oncology clinical development, including leading clinical act... 
Printer Friendly Version
05/04/15Tocagen Announces Updates from FDA Meeting and Clinical Data Presentations at AANS/CNS
Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors Following Meeting with FDA, Company Advances Towards Pivotal Phase 2/3 Trial in Patients with Recurrent High Grade Glioma WASHINGTON, D.C. – May 4, 2015 – Tocagen Inc. a clinical-stage immuno-oncology company, today announced updated interim data from Tocagen’s ongoing investigational studies were prese... 
Printer Friendly Version
04/30/15Tocagen Announces Presentations at the AANS/CNS Joint Section on Tumors
Tocagen to Present Updated Interim Results from Studies Evaluating Toca 511 & Toca FC at the American Association of Neurological Surgeons (AANS)/ Congress of Neurological Surgeons (CNS) Section on Tumors SAN DIEGO, – (April 30, 2015) — Tocagen Inc., a clinical-stage immuno-oncology company, today announced updated interim results from ongoing investigational studies of Toca 511 in combination with Toca FC will be presented by two principal investigators at the 11th Biennial Satellite Sym... 
Printer Friendly Version
02/25/15Tocagen Appoints Paul Schimmel, Ph.D, to the Board of Directors
Industry and Academic Leader Co-Founded Several Successful Biotechnology Companies, Including Alnylam, Cubist and Alkermes SAN DIEGO, – February 25, 2015 – Tocagen Inc., a clinical-stage cancer-selective immunotherapy company, today announced that Paul Schimmel, Ph.D., Hahn professor of molecular biology and chemistry at The Scripps Research Institute, has been appointed to the board of directors. Dr. Schimmel co-founded Alnylam Pharmaceuticals and currently serves as a member of the company’s... 
Printer Friendly Version